(Q41703695)

7 October 2017

Outpatient combination chemoimmunotherapy for patients with metastatic melanoma. Results of a phase I/II trial (English)

1 reference

7 October 2017

phase I clinical trial

0 references

phase II clinical trial

0 references

author name string

Kashani-Sabet M

1

1 reference

7 October 2017

Sagebiel RW

2

1 reference

7 October 2017

Collins HE

3

1 reference

7 October 2017

Glassberg AB

4

1 reference

7 October 2017

Allen RE

5

1 reference

7 October 2017

Leong SP

6

1 reference

7 October 2017

Small EJ

7

1 reference

7 October 2017

language of work or name

English

0 references

publication date

1 November 1999

1 reference

7 October 2017

1 reference

7 October 2017

86

1 reference

7 October 2017

10

1 reference

7 October 2017

2160-2165

1 reference

Phase II study of carmustine, dacarbazine, cisplatin, and tamoxifen in advanced melanoma: a Southwest Oncology Group study

7 October 2017

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991115%2986%3A10%3C2160%3A%3AAID-CNCR40%3E3.0.CO%3B2-W

Sequential chemoimmunotherapy in the treatment of metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991115%2986%3A10%3C2160%3A%3AAID-CNCR40%3E3.0.CO%3B2-W

Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991115%2986%3A10%3C2160%3A%3AAID-CNCR40%3E3.0.CO%3B2-W

Optimal two-stage designs for phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991115%2986%3A10%3C2160%3A%3AAID-CNCR40%3E3.0.CO%3B2-W

Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-alpha after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991115%2986%3A10%3C2160%3A%3AAID-CNCR40%3E3.0.CO%3B2-W

Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991115%2986%3A10%3C2160%3A%3AAID-CNCR40%3E3.0.CO%3B2-W

Increased effectiveness of interferon alfa-2b following active specific immunotherapy for melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991115%2986%3A10%3C2160%3A%3AAID-CNCR40%3E3.0.CO%3B2-W

Prospective randomized trial of the treatment of patients with metastatic melanoma using chemotherapy with cisplatin, dacarbazine, and tamoxifen alone or in combination with interleukin-2 and interferon alfa-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991115%2986%3A10%3C2160%3A%3AAID-CNCR40%3E3.0.CO%3B2-W

Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991115%2986%3A10%3C2160%3A%3AAID-CNCR40%3E3.0.CO%3B2-W

Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2819991115%2986%3A10%3C2160%3A%3AAID-CNCR40%3E3.0.CO%3B2-W

10.1002/(SICI)1097-0142(19991115)86:10<2160::AID-CNCR40>3.0.CO;2-W

21 January 2018

Identifiers

DOI

1 reference

7 October 2017

1 reference